Neptune’s krill oil battles CV disease three ways

An omega-3 phospholipid isolated from shrimp-like krill that ply the waters of the Antarctic Ocean may hold the key to a breakthrough cardiovascular therapeutic that helps reduce levels of serum triglycerides and “bad” LDL cholesterol, while helping to boost “good” HDL cholesterol. Neptune Technologies & Bioressources (NASDAQ:NEPT; TSX-V:NTB), which has been focused on commercializing patented [...]

Novadaq SPY deliveries to triple in second quarter

Novadaq Technologies (TSX:NDQ) expects to deliver about 70 of its SPY surgical imaging systems in the current second quarter, compared with 20 installations by its two partners in the first three months of 2011. The SPY fluorescence imaging system allows surgeons to intra-operatively capture, view and archive high quality image sequences of blood flow in [...]

Analysts hike price target on Theratechnologies

Versant Partners and Canaccord Genuity raised their price targets on Theratechnologies (TSX:TH) after the company signed a partnership with Sanofi-Aventis to distribute its Egrifta HIV treatment in Latin America, Africa and the Middle East, and confirmed that the U.S. selling price of the drug would be $23,900 (U.S.) a year, higher than previously assumed. Cannacord [...]

Versant ups Paladin Labs to buy

Versant Partners upgraded Paladin Labs (TSX:PLB) to “buy” from “neutral,” raising its 12-month price target to $31.50 from $29 after the company posted third quarter results. The stock was quoted at $28.01 Thursday afternoon. Analyst Doug Loe writes that while Paladin’s third quarter revenue was a bit lighter than projected, EBITDA was historically strong and [...]

Analysts cut Cardiome price target

Versant Partners and Dundee Securities have lowered their price targets on Cardiome Pharma (TSX:COM; NASDAQ:CRME) after it and partner Astellas Pharma halted a 470-patient Phase 3 trial testing an IV formulation of vernakalant or Kynapid for rapid-onset atrial fibrillation. Versant Partners analyst Doug Loe writes that the decision was “clearly disappointing because halting (the trial) [...]

Versant downgrades Transition to neutral

Versant Partners has downgraded Transition Therapeutics (TSX:TTH; NASDAQ:TTHI) to “neutral” from “buy” and slashed its price target to $3.25 from $6.25, citing Transition’s decision to discontinue development of its lead diabetes drug after it underperformed in a Phase 1/2  clinical trial. The stock has dropped 18% to $3.25 Friday morning, after trading as low as [...]

EU approves Cardiome’s Brinavess for IV

Cardiome Pharma’s (NASDAQ: CRME; TSX:COM) intravenous formulation of Brinavess has received marketing approval in the European Union, Iceland and Norway for the rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults. Patrick Magri, senior vice president, general manager, Cardiovascular Franchise, Merck (NYSE:MRK), said “we welcome this important milestone in our collaboration with [...]

Labopharm partner loses tramadol patent appeal

The U.S. Court of Appeals for the Federal Circuit has ruled that Purdue Pharma Products’ patent claims for controlled-release tramadol, a pain medication, are invalid.  Purdue distributes Labopharm’s (TSX:DDS; NASDAQ:DDSS) tramadol drug Ryzolt in the U.S. Generic drug maker Par Pharmaceutical (NYSE:PRX) had argued that the patent claims should be deemed invalid because they were [...]

Canadians’ data heading to ASCO

Versant Partners analyst Doug Loe has compiled a list of six biotech companies that will have data presented at the American Society of Clinical Oncology meeting on June 4 to 8.  He expects: · AEterna Zentaris (NASDAQ:AEZS; TSX:AEZ) to report final data from its 43-patient Phase 2 advanced ovarian cancer trial with its AEZS-108 drug, [...]

Oncolytics ready for final step with Reolysin

After a 10-year journey, Oncolytics Biotech (TSX:ONC; NASDAQ:ONCY ) is ready to take the final clinical step with its sole Reolysin drug as a treatment for a broad range of cancers. “Our product has really shown a breadth of activity in a wide variety of cancers that we had hoped it would way back when [...]

Next Page »